Reviva Pharmaceuticals’ (RVPH) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright reissued their buy rating on shares of Reviva Pharmaceuticals (NASDAQ:RVPH) in a research note issued to investors on Monday, Benzinga reports. HC Wainwright currently has a $20.00 price objective on the stock.

Separately, Benchmark reaffirmed a speculative buy rating and issued a $17.00 target price on shares of Reviva Pharmaceuticals in a report on Tuesday, April 16th.

Reviva Pharmaceuticals Price Performance

RVPH stock opened at $3.09 on Monday. The company has a 50-day moving average of $3.63 and a two-hundred day moving average of $4.12. The stock has a market capitalization of $86.27 million, a price-to-earnings ratio of -1.88 and a beta of -0.02. Reviva Pharmaceuticals has a 52-week low of $2.67 and a 52-week high of $9.25.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in RVPH. EMC Capital Management grew its position in Reviva Pharmaceuticals by 1,294.3% during the third quarter. EMC Capital Management now owns 123,915 shares of the company’s stock worth $613,000 after buying an additional 115,028 shares in the last quarter. Vontobel Holding Ltd. acquired a new stake in shares of Reviva Pharmaceuticals during the 4th quarter worth approximately $72,000. Finally, Armistice Capital LLC raised its stake in shares of Reviva Pharmaceuticals by 194.0% in the fourth quarter. Armistice Capital LLC now owns 1,764,000 shares of the company’s stock valued at $9,085,000 after purchasing an additional 1,164,000 shares in the last quarter. Institutional investors and hedge funds own 63.18% of the company’s stock.

About Reviva Pharmaceuticals

Reviva Pharmaceuticals Holdings, Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, cardiovascular, metabolic, and inflammatory diseases. The company's lead product candidate is brilaroxazine (RP5063), which is in Phase III clinical trials for use in the treatment of schizophrenia, as well as completed Phase I clinical trials to treat bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, Parkinson's disease psychosis, attention deficit hyperactivity disorder, pulmonary arterial hypertension, and idiopathic pulmonary fibrosis.